



MGFA SCIENTIFIC SESSION PROGRAM AND POSTERS

October 15, 2024
Savannah, Georgia @ the AANEM Annual Meeting

The Myasthenia Gravis Foundation of America (MGFA) Medical & Scientific Advisory Council presents a scientific session highlighting research in myasthenia gravis (MG) and myasthenic disorders. This session is the premier scientific symposium, globally, that focuses on the pathogenesis, immunology, diagnosis, and treatment of MG and related disorders of the neuromuscular junction. Included in the program are world renowned MG experts from both the scientific and clinical spaces.

Thank You to Our Steering Committee:
Diana Castro, MD, Neurology and Neuromuscular Care Center (Chair)
Neelam Goyal, MD, Stanford School of Medicine
Tuan Vu, MD, University of South Florida, Morsani College of Medicine

2024 MGFA Scientific Session Agenda

8:00 - 8:05am:	Welcome – Samantha Masterson, President and CEO, MGFA
8:05 – 8:10am:	Introduction of Keynote – Diana Castro, MD
8:10 – 8:45am:	Keynote Address: Mechanisms of Myasthenia Gravis Immunopathology – Kevin O’Connor, PhD
8:45 – 8:55am:	Q&A - Diana Castro, MD
8:55 – 8:57am:	Introduction to Biomarkers and Basic Science – Diana Castro, MD
8:57 – 9:04am:	Plasma Biomarker-Based Endotyping Reveals Distinct Inflammator Patters in Myasthenia Gravis Subtypes – Huahua Zhong, MD
9:04 – 9:18am:	A Serum Inflammatory Protein Biomarker Profile Defines Acetylcholine Receptor Antibody Seropositive Myasthenia Gravis and Visualization and Characterization of Complement Activation in Acetylcholine Receptor Antibody Seropositive Myasthenia Gravis – Anna Punga, MD, PhD
9:18 – 9:25am:	Imbalanced Pro-Inflammatory Immune Responses in Seropositive and Seronegative MG – Yingkai (Kevin) Li, MD
9:25 – 9:32am:	Alterations in Peripheral B and T Cell Subsets in MuSK-MG Subjects After Rituximab Treatment – Patricia Sikorski, PhD
9:32 – 9:39am:	Q&A
9:39 – 9:54am:	Break - Visit the exhibit tables
9:54 - 9:56am:	Introduction to Therapeutics – Neelam Goyal, MD
9:56 - 10:03am:	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study of Inebilizumab in Patients with Generalized Myasthenia Gravis (MINT): Topline Efficacy and Safety Findings – Richard Nowak, MS, MD
10:03 -10:10am:	Safety and Efficacy of BCMA-Directed mRNA CAR T-Cell Therapy in Generalized Myasthenia Gravis – Tuan Vu, MD
10:10 - 10:17am:	Preclinical Pharmacology of S-1117, a Novel Engineered FC-Fused IGG Cleaving Enzyme, for Chronic Treatment of Autoantibody-Mediated Diseases, Including Myasthenia Gravis – Julia Manasson, MD
10:17 – 10:24am:	NMD670, a First-in-Class Skeletal Muscle CLC-1 Inhibitor in Myasthenia Gravis: The Synapse-MG Dose-Finding Study – Vera Kiyasova, MD, PhD
10:24 – 10:31am:	Safety and Effectiveness of Nipocalimab in Adolescent Participants in the Open Label Phase 2/3 Vibrance-MG Clinical Study – Jonathan Strober, MD
10:31 – 10:38am:	Design of KYSA-6, a Phase 2, Open-Label, Multicenter Study of FYV-101, a Novel Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory Generalized Myasthenia Gravis – Aiden Haghikia, MD
10:38 – 10:45am:	Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 Vivacity-MG3 Study – Tuan Vu, MD
10:45 – 10:55am:	CLC-1 Inhibition Improves Skeletal Muscle Function in Rat Models and Patients with Myasthenia Gravis and CLC-1 Inhibition Improves QMG Score and Skeletal Muscle Function in Patients with Myasthenia Gravis – Martin Skov, PhD and Vera Kiyasova, MD, PhD
10:55 – 11:02am:	Q&A
11:02 – 11:04am:	Introduction to Patient Care and Hot Topics – Tuan Vu, MD
11:04 – 11:11am:	Developing Needs-Driven Medical Education for Healthcare Professionals in Myasthenia Gravis – James F. Howard Jr., MD
11:11- 11:18am:	The Myasthenia Gravis Patient Registry: Characteristics, Insights, and Learnings After a Decade (2013-23) – Kelly Gwathmey, MD
11:18 – 11:25am:	A Study of the Common Factors That Influence Fatigue in Myasthenia Gravis – Christopher Evans, Medical Student
11:25 – 11:32am:	Safety and Tolerability of Whole-Body Electrical Muscle Stimulation Exercise in Adults with Myasthenia Gravis: A Preliminary Analysis – Mamatha Pasnoor, MD
11:32 – 11:39am:	Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants Treated with Nipocalimab – Sheng Gao, PhD (updated 10/1)
11:39 – 11:46am:	Seronegative Myasthenia Gravis in Children with Autoinflammatory Syndromes – Alexander Fay MD, PhD
11:46 – 11:53am:	Exploring Outcomes and Characteristics of Myasthenia Gravis 2 (EXPLORE-MG2): Design, Rationale, and Baseline Results – Richard Nowak, MD, MS
11:53 – 11:59am:	Q&A
11:59 - 12:00pm:	Wrap up: Samantha Masterson, President and CEO, MGFA
12:00 – 12:45pm:	Poster session in Exhibit Hall B

MGFA Poster Directory

Below are accepted MGFA Scientific Session posters, organized by last name of the primary author. The MGFA poster number, starting with “MG,” will refer to the location of the poster (see floorplan below). Also included are the poster numbers listed in the Muscle & Nerve supplement published by AANEM.

91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114						
90	89	88	87	86	85	84	83	82	81	80	79	78	77	76	75	74	73	72	71	70	69	68	67	66	65	64	63	62	61
31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60
30	29	28	27	26	25	23	22	21	20	19	18	17	16	15	14	13	12	11	10	9	8	7	6	5	4	3	2	1	

MGFA Poster#	Muscle & Nerve#	First Name	Last Name	Credentials	Poster Title
MG 1	106	Samreen	Ahmed	MBBS	A Text Messaging-Based Patient Education Program Aimed at Improving Outcomes in Myasthenia Gravis
MG 2	40	Maria	Ait-Tihyaty	PhD	Disease Burden in Patients with Generalized Myasthenia Gravis
MG 3	78	Maria	Ait-Tihyaty	PhD	Partnering with Patients and Caregivers to Guide the Development of Impactful Study Engagement Tools in a Generalized Myasthenia Gravis Real World Study
MG 4	97	Maria	Ait-Tihyaty	PhD	Nipocalimab, a New Neonatal Fragment Crystallizable Blocker, Leads to Rapid, Substantial and Sustained Generalized Myasthenia Gravis Disease Control
MG 5	13	Mayra	Aldecoa	Fellow	Transcriptome-Wide and Stratified Genomic Structural Equation Modeling Identify Neurobiological Pathways Shared Across Myasthenia Gravis and Neuropsychiatric Disorders
MG 6	105	Priyanshu	Bansal	MD	Review of Efficacy of New Complement Inhibiting Monoclonal Antibodies in Myasthenia Gravis: A Real World Experience from a Tertiary Neurology Center
MG 7	54	Taylor	Bauman	BS	Is Residual Serum Fibrinogen a Biomarker for Myasthenia Gravis?
MG 8	65	Sara	Benitez	MD	Treatment Related Infection in Myasthenia Gravis
MG 9	56	Ratna	Bhavaraju-Sanka	MD	Patterns of Efgartigimod Dosing in Clinical Practice in the United States
MG 10	83	Alexandra	Bonner	MD	Determination of the Optimal Compound Muscle Action Potential Amplitude Decrement Cutoff Values in the Diagnosis of Myasthenia Gravis Using Repetitive Nerve Stimulation Studies
MG 11	60	Martin	Brandhoj Skov	PhD	Unmet Needs in Myasthenia Gravis: Patient and Physician Perspectives
MG 12	4	Jiaxin	Chen	MD, PhD	Therapeutic Plasma Exchange in AChR-Ab Positive Generalized Myasthenia Gravis: A Real World Study About Its Early Response
MG 13	21	Jiaxin	Chen	MD, PhD	Can Non-Thymomatous Late-Onset Myasthenia Gravis Benefit from Thymectomy? A Systematic Review and Meta-Analysis
MG 14	31	Pei	Chen	MD, PhD	Extraocular Muscle Volume on Time-Of-Flight Magnetic Resonance Angiography in Patients with Myasthenia Gravis
MG 15	32	Pei	Chen	MD, PhD	Conventional Dendritic Cells Are More Activated in the Hyperplastic Thymus of Myasthenia Gravis Patients
MG 16	67	Zia	Choudhry	MD, PhD, MBA	Leveraging AI to Characterize Mental Health Experiences Throughout the Myasthenia Gravis Diagnosis Journey
MG 17	68	Zia	Choudhry	MD, PhD, MBA	Uncontrolled Myasthenia Gravis Can Contribute to Additional Stress Burden and Adverse Mental Health Experiences
MG 18	69	Zia	Choudhry	MD, PhD, MBA	Sentiment Analysis of Digital Conversations Related to Myasthenia Gravis by Race/Ethnicity
MG 19	33	Marta	Cossu	MD, PhD	A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
MG 20	92	Dubravka	Dodig	MD, BSc, FRCPC	Dismantling of Neuromuscular Junction in Myasthenia Gravis - a Point of No Return

*Posters can be viewed at any time during the AANEM Annual Meeting in a special section of the Poster Hall on the first floor

MGFA Poster#	Muscle & Nerve#	First Name	Last Name	Credentials	Poster Title
MG 21	110	Eleni	Drakou	MD	Identifying Healthcare Disparities in Myasthenia Gravis: A Post-Covid-19 Pandemic Bronx Tale
MG 22	36	Rebecca	Dutta	MD	Recessive SYT2-Congenital Myasthenic Syndrome Caused by a Maternal Uniparental Disomy of Chromosome 1
MG 23	11	Christopher	Evans	MD (Candidate)	A Study of the Common Factors That Influence Fatigue in Myasthenia Gravis
MG 25	103	Constantine	Farmakidis	MD	Symptom Severity Assessment Using MG-ADL Items and Domains in a 24-Week, Phase 3 Study (Vivacity) of Nipocalimab in Generalized Myasthenia Gravis
MG 26	24	Alexander	Fay	MD, PhD	Seronegative Myasthenia Gravis in Children with Autoinflammatory Syndromes
MG 27	52	Miriam	Freimer	MD	Switching to Subcutaneous Zilucoplan from IV Complement Component 5 Inhibitors in Myasthenia Gravis: A Phase 3B Study
MG 28	61	Miriam	Freimer	MD	Corticosteroid Dose Tapering During Treatment with Zilucoplan in Patients with Generalized Myasthenia Gravis: 120-Week Follow-Up of Raise-Xt
MG 29	57	Rachana K.	Gandhi Mehta	MD	Self-Administration of Subcutaneous Rozanolixizumab in Patients with Generalized Myasthenia Gravis: Clinical Study Design
MG 30	1	Mariam	Gigilashvili	MD	Unique Case of Post-Covid-19 Myasthenia Gravis with Spontaneous Resolution
MG 31	63	Neelam	Goyal	MD	Real-World Reduction in Oral Corticosteroid Utilization at 1-Year Following Efgartigimod Initiation
MG 32	95	Jeffrey	Guptill	MD	Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis
MG 33	22	Kelly G.	Gwathmey	MD	Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part A of ADAPT NXT
MG 34	98	Kelly G.	Gwathmey	MD	Evaluation of the Indirect and Nonmedical Impacts of Generalized Myasthenia Gravis on Patients and Caregivers
MG 35	81	Ali A.	Habib	MD	Rozanolixizumab Treatment Patterns in Patients with Generalized Myasthenia Gravis: Post Hoc Analysis
MG 36	48	Aiden	Haghikia	MD	Design of KYSA-6, a Phase 2, Open-Label, Multicenter Study of KYV-101, a Novel Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory Generalized Myasthenia Gravis
MG 37	9	Lauren	Herrera	MD	Mismatch Between Neuromuscular Specialists and Myasthenia Gravis Patients in the U.S. Medicare Population
MG 38	102	James F.	Howard, Jr.	MD	Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults with Ocular MG
MG 39	37	James F.	Howard, Jr.	MD	Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
MG 40	74	James F.	Howard, Jr.	MD	Long-Term Safety and Efficacy of Zilucoplan in Generalized Myasthenia Gravis: 120-Week Interim Analysis of RAISE-XT
MG 41	75	James F.	Howard, Jr.	MD	Developing Needs-Driven Medical Education for Healthcare Professionals in Myasthenia Gravis
MG 42	99	James F.	Howard, Jr.	MD	The Phase 3 Prevail Study Assessing the Efficacy and Safety of Subcutaneous Gefurulumab in Adults with Generalized Myasthenia Gravis: Trial in Progress
MG 43	14	James F.	Howard, Jr.	MD	Development of a Myasthenia Gravis Patient Journey Map as a Tool to Identify Challenges and Unmet Needs in the Patient Community
MG 44	107	Sazan	Ismael	PhD	Developing MuSK L-CBAX to Detect Anti-MuSK Antibody
MG 45	70	Louis	Jackson	PharmD	Factors Influencing Exacerbations and Crises in Generalized Myasthenia Gravis: Findings from a Claims Database Study
MG 46	71	Louis	Jackson	PharmD	Impact of Race and Social Determinants of Health on Exacerbations in Generalized Myasthenia Gravis
MG 47	20	Henry	Kaminski	MD	Quantitating Factors Influencing the Myasthenia Gravis Telehealth Examination
MG 48	87	Henry	Kaminski	MD	Oral Cladribine Capsules for Generalized Myasthenia Gravis: Design of an Actively-Recruiting Phase 3 Clinical Study – the MyClad Study

MGFA Poster#	Muscle & Nerve#	First Name	Last Name	Credentials	Poster Title
MG 49	73	Hans	Katzberg	MD	Safety and Efficacy of Subcutaneous Immunoglobulin in Patients with Generalized Myasthenia Gravis
MG 50	34	Anosha	Khan		Towards a Genome-Wide Association for MuSK Myasthenia Gravis
MG 51	89	Fatemeh	Khani-Habibabadi	PhD	Distribution and Temporal Changes of Autoantibody-Mediated Pathogenic Mechanisms Among AChR-Positive MG Patients
MG 52	39	Vera	Kiyasova	MD, PhD	NMD670, a First-In-Class Skeletal Muscle CLC-1 Inhibitor in Myasthenia Gravis: The Synapse-MG Dose-Finding Study
MG 53	84	Vera	Kiyasova	MD, PhD	CLC-1 Inhibition Improves QMG Score and Skeletal Muscle Function in Patients with Myasthenia Gravis
MG 54	108	Tyler	Krall	BS	Clinical Outcomes of Adult Myasthenia Gravis Patients on Efgartigimod: A Retrospective Chart Review
MG 55	23	Yuebing	Li	MD, PhD	Epidemiological Study of Myasthenia Gravis in Elderly U.S. Population: A Longitudinal Analysis of the Medicare Claims Database from 2006-2019
MG 56	49	Huining	Li	Doctorate	Treatment Strategy Towards Myasthenia Gravis with GAD65-IgG Associated Neurological Disorders
MG 57	88	Yingkai (Kevin)	Li	MD	Imbalanced Pro-Inflammatory Immune Responses in Seropositive and Seronegative MG
MG 58	100	Cathy Meng Fei	Li	MD	Mediastinal Radiotherapy for Non-Operable Thymoma with Myasthenia Gravis
MG 59	94	Alexis	Lizarraga	MD	Comorbidities in Seropositive and Seronegative Myasthenia Gravis: A Single Center Experience
MG 60	15	Ching	Lum	PharmD	Pozelimab and Cemdisiran Combination Therapy in Patients with Myasthenia Gravis: Phase 3 Nimble Trial Design
MG 61	7	Sushan	Luo	MD, PhD	Clinical Outcome in Impending Myasthenic Crisis: A Prospective Cohort Study
MG 62	112	Lindsay	Malatesta	MD	Alternative Dosing of Efgartigimod in Myasthenia Gravis
MG 63	8	Julia	Manasson	MD	Preclinical Pharmacology of S-1117, a Novel Engineered Fc-Fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-Mediated Diseases Including Myasthenia Gravis
MG 64	58	Alexandra	McMillan	MS, MD	Simultaneous Myasthenia Gravis-Polymyositis Overlap Syndrome, a Case Report
MG 65	18	Lesley-Ann	Miller-Wilson	PhD, MS, MBA	Characteristics and Treatment Patterns of a United States Generalized Myasthenia Gravis Population: Interim Analysis of Real-World Data
MG 66	28	Lesley-Ann	Miller-Wilson	PhD, MS, MBA	Evidence Gap Analysis of the Burden of Disease and Treatment of Myasthenia Gravis
MG 67	46	Ali	Mousavi	MD	Enhanced Laboratory Detection of Anti-Acetylcholine Receptor Antibody Contributes to Rising Incidence Myasthenia Gravis
MG 68	93	Srikanth	Muppidi	MD	Observed Efficacy of Efgartigimod in Generalized Myasthenia Gravis Across Patient Subgroups in the Adapt-Sc+ Study
MG 69	5	Lauren	Nguyen	MSc	One Patient with Three Antibody-Confirmed Neurological Autoimmune Syndromes: A Case Report
MG 70	41	Richard	Nowak	MD, MS	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study of Inebilizumab in Patients with Generalized Myasthenia Gravis (MINT): Topline Efficacy and Safety Findings
MG 71	44	Richard	Nowak	MD, MS	The Myasthenia Gravis Patient Registry: Characteristics, Insights, and Learnings After a Decade (2013-23)
MG 72	86	Richard	Nowak	MD, MS	Change in Concomitant Immunosuppressive Therapies for Generalized Myasthenia Gravis in Patients Receiving Complement C5 Inhibitor Therapies: A Retrospective Analysis of Registry Data
MG 73	109	Richard	Nowak	MD, MS	Exploring Outcomes and Characteristics of Myasthenia Gravis 2 (EXPLORE-MG2): Design, Rationale, and Baseline Results
MG 74	111	Ananda	Pandurangadu	MD	Expediting Myasthenia Gravis Diagnostic Evaluation: A Novel, Proof-Of-Concept Tool for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment
MG 75	55	Shirali	Pandya	MPH, PhD	Incidence and Outcome of Meningococcal Infection with Eculizumab or Ravulizumab in Patients with gMG or NMOSD: An Analysis of U.S. Clinical Practice

MGFA Poster#	Muscle & Nerve#	First Name	Last Name	Credentials	Poster Title
MG 76	51	Robert M.	Pascuzzi	MD	Effect of Rozanolixizumab on Myasthenia Gravis–Specific Outcome Subdomain Scores: Post Hoc Analyses from the Phase 3 MycarinG Study
MG 77	114	Mamatha	Pasnoor	MD	Safety and Tolerability of Whole-Body Electrical Muscle Stimulation Exercise in Adults with Myasthenia Gravis: A Preliminary Analysis
MG 78	3	Sheryl	Pease	MBA	Assessing the Suitability of the Neuro-QoL Fatigue to Evaluate Fatigue in Patients Living with Myasthenia Gravis
MG 79	104	Tefani	Perera	MD	Feasibility of 12 Weeks of Remote Monitoring in Generalized Myasthenia Gravis
MG 80	12	Prashanth	Poulose	DM	Imaging Patterns in Congenital Myasthenic Syndrome (CMS) - Insights from MRI
MG 81	26	Anna	Punga	MD, PhD	Visualization and Characterization of Complement Activation in Acetylcholine Receptor Antibody Seropositive Myasthenia Gravis
MG 82	29	Anna	Punga	MD, PhD	Short-Term Changes in Serum Mirna Levels and Patient-Reported Outcomes in Myasthenia Gravis
MG 83	45	Anna	Punga	MD, PhD	Elevated C1S/C1-INH in Serum and Plasma of Myasthenia Gravis Patients
MG 84	47	Anna	Punga	MD, PhD	A Serum Inflammatory Protein Biomarker Profile Defines Acetylcholine Receptor Antibody Seropositive Myasthenia Gravis
MG 85	17	Manvi	Punukollu	BS	Comparative Efficacy of Treatment Modalities in Myasthenia Gravis
MG 86	59	Cynthia	Qi	MBA	Exploring the Impact of Nonsteroidal Immunosuppressive Drugs and Steroids on the Development of Comorbidities in Patients with Myasthenia Gravis in the National Veterans Affairs Health Network
MG 87	80	Cynthia	Qi	MBA	Quality of Life of Ocular MG Patients with Persistent Symptoms: Comparison with the General Population
MG 88	25	Chuan	Qin	MD, PhD	Anti-BCMA CAR T-Cell Therapy in Patients with Refractory Myasthenia Gravis
MG 89	35	Vijayaraghava	Rao	PhD	Steroid Use, Toxicity, and Monitoring in Patients with Generalized Myasthenia Gravis: A Survey of Neurologists in the United States
MG 90	90	Bhaskar	Roy	MBBS	Proteomic Analysis Reveals a Distinct Immunological Signature for Late-Onset Myasthenia Gravis
MG 91	101	Chloe	Sader	PharmD	Safety Outcomes in Pregnant Patients Treated with the Complement 5 Inhibitor Therapy (C5IT) Eculizumab
MG 92	85	Christopher A.	Scheiner	MD, PhD	Outcomes for Patients with Generalized Myasthenia Gravis Prescribed Ravulizumab, Eculizumab, or Efgartigimod Treatment: Interim Analysis of a Retrospective Medical Record Analysis (Elevate)
MG 93	76	John	Sheehan	PhD	Perinatal Treatment Patterns in Myasthenia Gravis
MG 94	77	John	Sheehan	PhD	Adverse Pregnancy Outcomes in Myasthenia Gravis: A Retrospective Cohort Study in a U.S. Health Insurance Claims Database
MG 95	96	Patricia	Sikorsi	PhD	Alterations in Peripheral B and T Cell Subsets in MuSK-MG Subjects After Rituximab Treatment
MG 96	19	Nicholas	Silvestri	MD	Real-World Experience with Individualized Dosing of Efgartigimod in Patients with Generalized Myasthenia Gravis
MG 97	82	Martin	Skov	PhD	CLC-1 Inhibition Improves Skeletal Muscle Function in Rat Models and Patients with Myasthenia Gravis.
MG 98	72	A. Gordon	Smith	MD	Comparative Risk-Benefit Profiles of Immunomodulatory Therapies for Patients with Generalized Myasthenia Gravis
MG 99	2	Hunter	Soleymani	MD	Clinical Eyelid Myotonia in Myasthenia Gravis
MG 100	66	Jonathan	Strober	MD	Safety and Effectiveness of Nipocalimab in Adolescent Participants in the Open Label Phase 2/3 Vibrance-MG Clinical Study
MG 101	16	Ryan	Verity	MD	Efgartigimod Alfa-Fcab Use in a Pregnant Woman with Generalized Myasthenia Gravis: A Case Report
MG 102	43	Tuan	Vu	MD	Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 Vivacity-MG3 Study
MG 103	53	Tuan	Vu	MD	Rozanolixizumab in Patients Aged ≥65 Years with Generalized Myasthenia Gravis: A Post Hoc Analysis of the Phase 3 MycarinG Study

MGFA Poster#	Muscle & Nerve#	First Name	Last Name	Credentials	Poster Title
MG 104	79	Tuan	Vu	MD	Non-Steroidal Immunosuppressant Therapy Changes During Treatment with Zilucoplan in Patients with Generalized Myasthenia Gravis: 120-Week Follow-Up of RAISE-XT
MG 105	91	Tuan	Vu	MD	Safety and Efficacy of BCMA-Directed mRNA CAR T-Cell Therapy in Generalized Myasthenia Gravis
MG 106	27	Haiyan	Wang	PhD	Fast-Acting Treatment of Myasthenic Crisis with Efgartigimod from the Perspective of the Neonatal Intensive Care Unit
MG 107	62	Michael D.	Weiss	MD	Concomitant Intravenous Immunoglobulin or Plasma Exchange Has No Effect on Complement Inhibition by Zilucoplan
MG 108	42	Lauren	Williams	BS	Clinical Experience with Rozanolixizumab for Treatment of Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis
MG 109	38	Ge	Xiong	MD, PhD	A Retrospective Case Series of Myasthenia Gravis Associated with Immune Checkpoint Inhibitors
MG 110	50	Jingwen	Yan	MD	The Mitochondrial Quality Control Mechanism of Statins Affecting Myasthenia Gravis Patients with Hyperlipidemia
MG 111	30	(updated 10/1) Sheng	Gao	PhD	Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants Treated with Nipocalimab
MG 112	113	Li	Zhang	MD	Acetylcholine Receptor Antibodies as a Biomarker of Treatment Strategy with Rituximab in Myasthenia Gravis
MG 113	6	Huahua	Zhong	MD	Plasma Biomarker-Based Endotyping Reveals Distinct Inflammatory Patterns in Myasthenia Gravis Subtypes
MG 114	10	Min	Zhu	MD, PhD	Lambert-Eaton Myasthetic Syndrome May Not Be Coincidental in Prostate Cancer

**We thank our generous industry partners and sponsors.
We appreciate your ongoing commitment to the MG community.**

Presenting Partners



Collaborating Partner



Supporting Partner





To view this program on your mobile device, scan here.



For more information, visit myasthenia.org
Contact us at mgfa@myasthenia.org

